Additionally, clinical studies are needed to assess the expression levels of METTL14, OTUD7B, and HIF-1α in patient populations at risk for advanced ESCC, which could lead to the identification of biomarkers for early detection and risk stratification. This evidence concerns the gene METTL14 and esophageal squamous cell carcinoma.